RxDoctor Payments Data

William Nash, MD

Family Medicine · Nashville, GANPI 1235172628

Payments from drug & device makers

$1,080in general payments, 2019–2025

Across 36 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$167
  • Amgen$130
  • AstraZeneca$124
  • Otsuka America Pharmaceutical, Inc.$93
  • Bayer$78
  • Lilly USA, LLC$77
  • plus $411 from 13 others

What the payments were for

  • Food & beverage$1,06599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,080 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$121,990
Medicare patients
249
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$161,585
MounjaroTirzepatide145$151,668
JardianceEmpagliflozin146$109,086
TradjentaLinagliptin151$94,610
MyrbetriqMirabegron182$91,222
PercocetOxycodone Hcl/Acetaminophen13$79,728
JanuviaSitagliptin Phosphate91$63,805
OzempicSemaglutide53$59,381
NuedextaDextromethorphan Hbr/Quinidine22$34,375
JanumetSitagliptin Phos/Metformin Hcl22$31,776
RexultiBrexpiprazole25$29,811
Repatha SureclickEvolocumab44$28,897
Tresiba Flextouch U-100Insulin Degludec116$23,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,399
KerendiaFinerenone32$19,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$15$203,696297 claims
Lilly USA, LLCMounjaro, Trulicity$77$171,321163 claims
Novo NordiskOzempic, Rybelsus$54$76,74667 claims
Avanir Pharmaceuticals, Inc.Nuedexta$20$34,37522 claims
GSKTrelegy Ellipta, Shingrix$16$30,76168 claims
Otsuka America Pharmaceutical, Inc.Rexulti$93$29,81125 claims
BayerKerendia$78$19,93032 claims
AbbVieLinzess$16$18,15430 claims
AstraZenecaBreztri Aerosphere$124$12,38519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Nashville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →